release testing
Recently Published Documents


TOTAL DOCUMENTS

157
(FIVE YEARS 45)

H-INDEX

20
(FIVE YEARS 5)

Author(s):  
Elliot Lilley ◽  
Richard Isbrucker ◽  
Ian Ragan ◽  
Anthony Holmes

Author(s):  
Katrin I. Tiffner ◽  
Isadore Kanfer ◽  
Thomas Augustin ◽  
Reingard Raml ◽  
Sam G. Raney ◽  
...  

Author(s):  
Sonia M. Lombardo ◽  
Nazende Günday Türeli ◽  
Marcus Koch ◽  
Marc Schneider ◽  
Akif E. Türeli

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1313
Author(s):  
Yejin Kim ◽  
Eun Ji Park ◽  
Tae Wan Kim ◽  
Dong Hee Na

Biopolymeric microparticles have been widely used for long-term release formulations of short half-life chemicals or synthetic peptides. Characterization of the drug release from microparticles is important to ensure product quality and desired pharmacological effect. However, there is no official method for long-term release parenteral dosage forms. Much work has been done to develop methods for in vitro drug release testing, generally grouped into three major categories: sample and separate, dialysis membrane, and continuous flow (flow-through cell) methods. In vitro drug release testing also plays an important role in providing insight into the in vivo performance of a product. In vitro release test with in vivo relevance can reduce the cost of conducting in vivo studies and accelerate drug product development. Therefore, investigation of the in vitro–in vivo correlation (IVIVC) is increasingly becoming an essential part of particulate formulation development. This review summarizes the principles of the in vitro release testing methods of biopolymeric particulate system with the recent research articles and discusses their characteristics including IVIVC, accelerated release testing methods, and stability of encapsulated drugs.


2021 ◽  
Vol 22 (11) ◽  
pp. 5824
Author(s):  
Silvia Carloni ◽  
Claudia Piccinini ◽  
Elena Pancisi ◽  
Valentina Soldati ◽  
Monica Stefanelli ◽  
...  

For many years, oncological clinical trials have taken advantage of dendritic cells (DC) for the design of DC-based cellular therapies. This has required the design of suitable quality control assays to evaluate the potency of these products. The purpose of our work was to develop and validate a novel bioassay that uses flow cytometry as a read-out measurement. In this method, CD3+ cells are labeled with a fluorescent dye and the DC costimulatory activity is measured by the degree of T cell proliferation caused by the DC–T cell interaction. The validation of the method was achieved by the evaluation of essential analytical parameters defined by international guidelines. Our results demonstrated that the method could be considered specific, selective, and robust. The comparison between measured values and estimated true values confirmed a high level of accuracy and a lack of systematic error. Repeated experiments have shown the reproducibility of the assay and the proportionality between the potency and the DC amount has proven its linearity. Our results suggest that the method is compliant with the guidelines and could be adopted as a quality control assay or batch-release testing within GMP facilities.


Author(s):  
Shaolong He ◽  
Jette Jacobsen ◽  
Carsten Uhd Nielsen ◽  
Natalja Genina ◽  
Jesper Østergaard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document